An FDA-approved GHRH analog specifically indicated for HIV-associated lipodystrophy and visceral fat reduction.
Molecular Weight
5135.8 Da
Half-Life
~26 minutes
Typical Dose
1–2 mg daily
Cycle Length
6–12 months
Description
Tesamorelin (Egrifta) is a synthetic analog of the full 44-amino acid GHRH, stabilized by the addition of a trans-3-hexenoic acid group that protects it from dipeptidyl peptidase IV (DPP-IV) degradation and extends its activity. It was FDA-approved in 2010 for the treatment of HIV-associated lipodystrophy — a condition characterized by excess visceral fat accumulation caused by antiretroviral therapy. Tesamorelin is more potent than sermorelin due to its full-length GHRH sequence and enhanced stability. The LIPO-010 trial demonstrated a 15.2% reduction in visceral adipose tissue (VAT) compared to placebo over 26 weeks. Beyond its approved indication, tesamorelin is increasingly used off-label for general body composition optimization, anti-aging, and cognitive enhancement (emerging data suggests GH optimization may improve cognitive function in aging populations).
Key Characteristics
Molecular FormulaC221H366N72O67S
Molecular Weight5135.8 Da
Half-Life~26 minutes
Administration RoutesSubcutaneous injection
Typical Dose1–2 mg daily
FrequencyOnce daily
Investigated Benefits
Significant visceral fat reduction
Increased GH and IGF-1
Improved body composition
Reduced cardiovascular risk factors
Improved cognitive function (emerging data)
* Benefits based on preclinical/animal research unless otherwise noted.
Peptide Protocol Education Portal
Members-Only Access
Access advanced peptide education, protocol insights, and research-based information curated for informed users. Create a free account or log in to continue.
Please acknowledge the disclaimer above to continue.